

# Journal Pre-proof

High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California

George Cholankeril, MD, Alexander Podboy, MD, Vasiliki Irene Aivaliotis, MD, Branden Tarlow, MD, PhD, Edward A. Pham, MD, PhD, Sean Spencer, MD, PhD, Donghee Kim, MD, PhD, Ann Hsing, PhD, Aijaz Ahmed, MD

PII: S0016-5085(20)30471-6  
DOI: <https://doi.org/10.1053/j.gastro.2020.04.008>  
Reference: YGAST 63354

To appear in: *Gastroenterology*  
Accepted Date: 4 April 2020

Please cite this article as: Cholankeril G, Podboy A, Aivaliotis VI, Tarlow B, Pham EA, Spencer S, Kim D, Hsing A, Ahmed A, High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California, *Gastroenterology* (2020), doi: <https://doi.org/10.1053/j.gastro.2020.04.008>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 by the AGA Institute



**Title: High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California**

**Authors: George Cholankeril, MD<sup>1,2\*</sup>, Alexander Podboy, MD<sup>1\*</sup>, Vasiliki Irene Aivaliotis, MD<sup>1</sup>, Branden Tarlow, MD, PhD<sup>1</sup>, Edward A. Pham, MD, PhD<sup>1</sup>, Sean Spencer MD, PhD<sup>1</sup>, Donghee Kim, MD, PhD<sup>1</sup>, Ann Hsing, PhD<sup>2</sup>, Aijaz Ahmed, MD<sup>1</sup>**

**Author Affiliations:**

<sup>1</sup> Division of Gastroenterology and Hepatology, Stanford University School of Medicine,

Redwood City, CA 94603, USA

<sup>2</sup> Department of Epidemiology and Population Health, Stanford University School of Medicine,

Stanford, CA 94305, USA

**\* Author names in bold designate shared co-first authorship**

**Word Count (not including tables and references): 1000**

**Author correspondences:**

George Cholankeril, MD  
Stanford University School of Medicine  
Division of Gastroenterology and Hepatology  
430 Broadway, Pavilion C-3rd Floor, GI Suite,  
Redwood City, CA 94063.  
E-mail: georgetc@stanford.edu  
Phone: (914) 215-2683

Alexander Podboy, MD  
Stanford University School of Medicine  
Division of Gastroenterology and Hepatology  
430 Broadway, Pavilion C-3rd Floor, GI Suite,  
Redwood City, CA 94063.  
E-mail: apodboy@stanford.edu  
Phone: (678) 956-4716

**Acknowledgment Section:**

**Conflict of Interest Disclosures:** None of the authors (G.C., A.P, V.A, B.T, E.A.P., S.P.S, D.K., A.H., and A.A) have any relevant conflict of interest or other financial disclosures relevant to the subject matter.

**Author Contributions:** A.P. and G.C. equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version. B.T., V.A., S.P.S. assisted in data acquisition, manuscript preparation and critical appraisal of the manuscript. A.H., D.K., and A.A. provided critical appraisal of the manuscript.

**Funding/ Grant Support:** G.C., B.T., S.P.S., and E.A.P supported by NIH Training Grant T32DK007056. None of the authors received financial or material support for the research and work in this manuscript.

**Acknowledgments:** We would like to thank our program director, David Limsui, for his tireless dedication to our medical education and to all the front line healthcare workers across the globe combatting the current pandemic.

## **Introduction**

The current pandemic caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), continues to spread, and as of April 1, 2020, over 920,000 cases have been reported worldwide.<sup>1</sup> While the respiratory complications of SARS-CoV-2 have been described, the impact on the gastrointestinal and hepatic systems remains unknown, with conflicting levels noted in preliminary cases from China and Singapore.<sup>2-4</sup> We aim to characterize the gastrointestinal manifestations in patients with SARS-CoV-2 at our institution.

## **Methods**

We performed a retrospective analysis on data collected from consecutive patients who presented to our institution between March 04, 2020, and March 24, 2020. All patients had confirmed SARS-CoV-2 infection based on a positive polymerase chain reaction testing. An expedited approval from our Institutional Review Board was obtained. In addition to the symptoms reported by the patients at presentation, demographic, clinical and laboratory data were evaluated. Frequencies of categorical variables and the means  $\pm$  standard deviation (SD) or median (interquartile range [IQR]) of the continuous variables were calculated. Data were collected and analyzed using SAS 9.4 (Charlotte, NC).

## **Results**

### Baseline Characteristics and Clinical Course

A total of 116 patients with confirmed SARS-CoV-2 were identified. Clinical characteristics and demographic data are described in Table 1. Overall, the median age was 50 years [IQR, 35-67]

with a higher distribution of males (53.4%) and Caucasians (50.9%). 27.9% were noted to have a BMI > 30. 11.6% of patients were noted to be healthcare practitioners or allied staff.

The most common symptoms at presentation included cough (94.8%), fever (76.7%), dyspnea (58%), and myalgias (52.2%). The median duration of these respiratory symptoms was 5.0 [IQR, 3-7] days. With regards to admission status, 83 patients (71.6%) were evaluated in the emergency room or clinic only, 24 (20.7%) were admitted to the general medical floor, and 9 (7.8%) were admitted to the intensive care unit (ICU). The average length of stay for patients only admitted to the general floor was 5.0 days (SD, 3.9) vs 10.5 days (SD, 0.5) for patients that required ICU level care. 5 patients were still hospitalized at the time of this report and one patient died at hospital day 11.

#### Gastrointestinal and Hepatic manifestations

Gastrointestinal symptoms were reported by 31.9% of patients, with 89.2% describing their gastrointestinal complaints as mild (Table 1). Loss of appetite (22.3%), nausea/vomiting (12.0%) and diarrhea (12.0%) were the most common gastrointestinal symptoms. None of the patients developed isolated gastrointestinal symptoms or gastrointestinal symptoms as an initial manifestation of SARS-CoV-2 infection. Median duration of gastrointestinal-specific symptoms including nausea/vomiting or diarrhea was 1 day [IQR 0-4]; which was significantly shorter than the duration of respiratory symptoms ( $P < 0.001$ ).

65 patients underwent laboratory testing that included liver enzymes and total bilirubin levels at presentation; with 26 patients (40%) demonstrating hepatic dysfunction. 22 of the 26 patients with liver enzyme elevations were noted to have baseline liver enzymes that were within normal limits. All four patients with baseline abnormalities in liver enzymes were noted to have at least

a two-fold elevation in liver enzymes during their SARS-CoV-2 disease course. Among those with abnormalities in liver chemistries, we noted slightly higher levels of aspartate aminotransferase (AST) compared to alanine aminotransferase (ALT) as shown in Table 1. No cases of elevated alkaline phosphatase were identified. Two patients had abnormal bilirubin levels during their presentation however they also had abnormal bilirubin levels at baseline.

The severity of overall illness and level of care were associated with aspartate aminotransferase levels at the time of presentation (Pearson coefficient 0.33,  $P = 0.009$ ). No other variables, including presence of gastrointestinal disease, correlated to disease severity.

## Discussion

To our knowledge this is the largest published analysis of an American cohort of patients diagnosed with SARS-CoV-2. We noted that a significant proportion (31.9%) of patients experience concurrent gastrointestinal symptoms prior to presentation. Additionally, elevations in AST levels correlated to severity of disease. However, none of the patients in this cohort developed gastrointestinal symptoms as the initial presentation or as isolated symptomatology of SARS-CoV-2 infection.

Previous reports of gastrointestinal symptomatology in SARS-CoV-2 have varied, with estimates ranging from 5-50%.<sup>2-3</sup> While, the etiology for the gastrointestinal symptoms noted in SARS-CoV-2 is unknown; ACE2, a cellular receptor, appears to play a critical role in the life cycle and pathogenesis of SARS-CoV-2 and is widely expressed throughout the gastrointestinal tract.<sup>4</sup> Isolated AST involvement can potentially indicate a non-hepatic etiology, however autopsy reports of a patient with severe SARS-CoV-2 infection revealed moderate microvesicular

steatosis with mild lobular and portal inflammatory activity suggestive of direct viral injury within the liver, compared to only minimal interstitial mononuclear inflammatory infiltrates in cardiac biopsies.<sup>5</sup> Additionally, in a sub-analysis of our data, 43 patients were screened for cardiac injury with troponin I or T enzyme levels, and only 3 were noted to have positive cardiac biomarkers. Interestingly, 2/3 of these patients were noted to have normal AST values.

There are several limitations to our analysis. This is a single institution study leading to the possibility of regional bias, and caution is needed prior to generalizing our experience.

However, according to public health reports over our study period, a total of 364 cases of SARS-CoV-2 were identified in our county (Santa Clara County, CA), and the 116 patients at our institution represent over 30% of the total reported cases, potentially aiding the generalizability of our observations.<sup>13</sup> Also, the decision to obtain liver function tests was not controlled, leading to the potential for recall bias. As evaluation of SARS-COV2 at our hospital was streamlined, exhaustive documentation of non-respiratory symptoms may be incomplete. Moreover, testing was currently only offered under specific criteria (that required pulmonary symptoms) and could have missed patients with gastrointestinal symptoms only, thereby underestimating the true prevalence of gastrointestinal involvement. It is also unclear if our results can be extrapolated to asymptomatic or minimally symptomatic patients that do not seek medical care.

In summary, our results add to the growing body of literature that note a significant proportion of concurrent gastrointestinal manifestations related to the SARS-CoV-2. Elevation in AST levels was the lone variable correlated to disease activity.

**References:**

1. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Situation Report – 71. 2020. Available at: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200326-sitrep-71-covid-19.pdf?sfvrsn=9e5b8b48\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200326-sitrep-71-covid-19.pdf?sfvrsn=9e5b8b48_2). Accessed: April 1, 2020.
2. Guan WJ, et al. Clinical characteristics of 2019 novel coronavirus infection in China. *N Engl J Med.* 2020; (published online Feb 28.) DOI:10.1056/NEJMoa2002032
3. Young BE, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA* 2020.  
doi:10.1001/jama.2020.3204pmid:<http://www.ncbi.nlm.nih.gov/pubmed/32125362>
4. Gu J, et al. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission, *Gastroenterology* (2020). doi: <https://doi.org/10.1053/j.gastro.2020.02.054>.
5. Xu Z, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respiratory Medicine*. Feb 2020. DOI:[https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X)
6. Covid19.direct. Available at: <https://covid-19.direct/county/CA/Santa%20Clara>. Accessed March 26 2020.
7. Shi S, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol.* Mar 2020.  
doi:10.1001/jamacardio.2020.0950
8. Han C, et al. Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *American J Gastro.* 2020. March. Available at:  
[https://journals.lww.com/ajg/Documents/COVID\\_Digestive\\_Symptoms\\_AJG\\_Preproof.pdf](https://journals.lww.com/ajg/Documents/COVID_Digestive_Symptoms_AJG_Preproof.pdf)

**Author names in bold designate shared co-first authorship**

Journal Pre-proof

**Table 1.** Clinical characteristics, gastrointestinal symptoms and liver chemistries at presentation in patients with SARS-CoV-2 Infection, median [IQR] or N (%).

	N=116
<b>Age</b>	50 [35-67]
<b>Male</b>	62 (53.4)
<b>Race/Ethnicity</b>	5 (4.3)
Caucasian	59 (50.9)
Hispanic	25 (21.9)
Asian	25 (21.9)
<b>BMI</b>	25.8 [23.2-31.5]
<b>Smoking History</b>	
Current Smoker	3 (2.8)
Former Smoker	21 (23.3)
<b>History of Recent Travel</b>	
Domestic	17 (14.8)
International	16 (13.6)
Cruise	3 (2.6)
<b>Healthcare worker</b>	13 (11.6)
<b>Known Exposure to COVID</b>	39 (33.9)
<b>Past Medical History</b>	

Chronic Liver Disease	3 (2.8)
Chronic Pulmonary Disorder	24 (20.7)
Hypertension	32 (27.8)
Diabetes	19 (16.4)
Cardiovascular Disease	15 (12.9)
Metabolic Syndrome	10 (8.6)
Chronic Kidney Disease	4 (3.5)
<b>Medication Use</b>	
ACE/ARB	14 (12.1)
Chronic immunosuppression	4 (4.3)
<b>Any GI Symptoms</b>	37 (31.9)
Nausea and/or vomiting	12 (10.3)
Diarrhea	12 (10.3)
Nausea/Vomiting and Diarrhea	5 (4.3)
Abdominal Pain	10 (8.8)
Loss of Appetite	22 (25.3)
Duration of Nausea/Vomiting or Diarrhea, days	1 [0-4]
<b>Liver Function Tests [LFT]</b>	<b>N=65</b>
Aspartate aminotransferase [AST], (u/L)	35 [22-58]

Alanine aminotransferase [ALT], (u/L)	32 [22-48]
Alkaline phosphatase [ALP], (u/L)	67 (53-85)
Total bilirubin, (mg/dl)	0.4 [0.3-0.7]
<b>Patients with Abnormal LFT</b>	<b>N=26</b>
Aspartate aminotransferase [AST], (u/L)	64 [24-76]
Alanine aminotransferase [ALT], (u/L)	59 (22-76)
Alkaline phosphatase [ALP], (u/L)	75 (53-89)
Total bilirubin, (mg/dl)	0.5 [0.3-0.7]